<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784756</url>
  </required_header>
  <id_info>
    <org_study_id>UHN-TID-003</org_study_id>
    <nct_id>NCT02784756</nct_id>
  </id_info>
  <brief_title>Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients</brief_title>
  <acronym>QFT-CMV</acronym>
  <official_title>Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multi-Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian National Transplant Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will prospectively determine the clinical utility of CMV cell-mediated immunity
      using the Quantiferon test. The investigators will use the assay results to tailor the
      duration of CMV prophylaxis in solid organ transplant patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytomegalovirus (CMV) disease is an important cause of morbidity in solid organ
      transplantation recipients and remains the most common opportunistic viral infection in these
      patients. Standard CMV prevention strategies include universal prophylaxis and pre-emptive
      therapy with viral load monitoring. However, neither of these strategies has been successful
      in eliminating CMV disease as seen by high rates of viremia, incidence, and CMV recurrence
      despite treatment. Recently, the Quantiferon-CMV assay has been shown to predict late CMV
      reactivation after prophylaxis and to be predictive of viral progression and the need for
      antiviral therapy in organ transplant recipients who develop low level CMV viremia. The
      purpose of the current study is to test the clinical strategy of using the Quantiferon-CMV
      assay in guiding the duration of primary CMV prophylaxis in solid organ transplant patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with symptomatic CMV disease (including viral syndrome and tissue invasive disease) at 1 year post-transplant.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of CMV viremia as measured by QuantiFERON-CMV assay (&gt; 1000 IU/mL)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of positive vs. negative cell-mediated immunity assays post-transplant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cytomegalovirus Viraemia</condition>
  <arm_group>
    <arm_group_label>Quantiferon-CMV assay</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will receive a CMV-immunity test at specific time points during the study. This is a single arm design</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Quantiferon-CMV assay</intervention_name>
    <arm_group_label>Quantiferon-CMV assay</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult kidney, kidney-pancreas, liver transplant recipient, or heart transplant
             recipient

          -  CMV D+/R- patient or any R+ patient who received antithymocyte globulin induction
             therapy

        Exclusion Criteria:

          -  Unable to comply with protocol

          -  Campath (Alemtuzumab) induction

          -  Receiving another investigational compound for CMV treatment or prophylaxis.

          -  Allergy to valganciclovir or ganciclovir

          -  Receiving an investigational compound for prevention or treatment of rejection, or
             participating in another interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul Humar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deepali Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deepali Kumar, MD, FRCP(C)</last_name>
    <phone>416-340-4241</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Cervera, MD</last_name>
      <phone>780-492-0278</phone>
      <email>cerveraa@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sonia Fuentes, MD</last_name>
      <phone>780-492-0278</phone>
      <email>fuentesr@ualberta.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital - Providence Health</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Gill, MD</last_name>
      <phone>604-682-2344</phone>
      <phone_ext>64707</phone_ext>
      <email>JGill@providencehealth.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seyed Hosseini, MD</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>3476</phone_ext>
      <email>seyed.hosseini@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Samantha Parsons</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>3476</phone_ext>
      <email>samantha.parsons@lhsc.on.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Zaltzman, MD</last_name>
      <phone>416-867-7444</phone>
      <email>zaltzmanj@smh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Nash</last_name>
      <phone>416-867-3692</phone>
      <email>nashm@smh.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Health Network, Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Pinzon</last_name>
      <phone>416-340-4800 7393</phone>
      <phone_ext>7393</phone_ext>
      <email>Natalia.Pinzon@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Fernandez, MD</last_name>
      <phone>+349136908000</phone>
      <phone_ext>4631</phone_ext>
      <email>mario_fdezruiz@yahoo.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quantiferon-CMV</keyword>
  <keyword>solid organ transplant</keyword>
  <keyword>CMV Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viremia</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

